Although several studies have reported interleukin over-expression in K-ras positive cancer patients [18], [19], this is the first time that IL-17, IL-22, and IL-23 are associated with K-ras-linked cancer stage-specific over-expression. This evidence concerns the gene IL17A and cancer.